医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Bioasis Announces Registration and Grant Notice of Patent Application in China Relating to xB3 Platform Technology for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier

2019年08月22日 AM05:05
このエントリーをはてなブックマークに追加


 

GUILFORD, Conn.

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announces that the China National Intellectual Property Administration (CNIPA, formerly SIPO) issued a Notice to Undergo Registration Procedures and a Notice to Grant Patent Rights for a Chinese patent application for the Company’s platform technology.

The patent application relates to Bioasis’ P97 conjugates with therapeutic agents where P97 has the ability to transport the agent across the BBB. These conjugates include xB3-001, Bioasis’ lead product conjugate with trastuzumab in development for the treatment of HER2+ breast cancer brain metastases. The allowed claims of this patent application also cover pharmaceutical compositions containing the conjugates.

“We are excited about the allowance of this patent application by CNIPA, because this represents a major milestone for our intellectual property protection around our core assets in the largest market in Asia,” said Company Chair and Chief Executive officer Deborah Rathjen, Ph.D.

“The treatment of HER2+ breast cancer brain metastases is an area of significant unmet need which Bioasis’ platform technology for blood-brain barrier drug delivery seeks to address. Whilst trastuzumab is a very effective treatment for HER2+ breast cancer and peripheral metastases, it is not able to enter the brain without conjugation to Bioasis’ proprietary peptides. Our xB3-001 has the potential to be the next standard of care for treatment of both peripheral and CNS HER2+ breast cancer metastases,” Dr Rathjen added.

About Bioasis

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 platform, a proprietary technology for the delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. Bioasis’ internal pipeline programs are focused on treatments for orphan indications, including certain brain cancers, and rare diseases, including Gaucher’s Disease Type II. The Company maintains headquarters in Guilford, Connecticut. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the Company, please visit www.bioasis.us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190821005536/en/

CONTACT

Deborah Rathjen

deborah@bioasis.us

+1 203 533 7082

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates